Literature DB >> 8195614

Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group.

K H Fife1, C S Crumpacker, G J Mertz, E L Hill, G S Boone.   

Abstract

Questions have arisen regarding the clinical outcome and the possible selection of resistant virus when patients with genital herpes discontinue prolonged chronic acyclovir; 239 immunocompetent patients with a history of frequently recurring genital herpes who stopped successful suppressive therapy after 6 years were studied. Of the patients, 85.8% had at least one recurrence and 75% had at least two recurrences in the subsequent year (median time to first and second recurrence, 68 and 180 days, respectively). Herpes simplex virus isolates recovered from these patients had a median acyclovir sensitivity of 0.79 micrograms/mL and 4 (3.5%) were resistant (> or = 3 micrograms/mL). These values are comparable to those of pretherapy isolates and to reported values of isolates from acyclovir-naive patients. Also, paired pre- and posttherapy isolates from 13 patients showed no trend toward development of resistance. Thus, even after 6 years of acyclovir suppression, most patients continue to have recurrences, but the selection of resistant virus has not been observed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195614     DOI: 10.1093/infdis/169.6.1338

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

Review 1.  Genital herpes simplex virus infection in the adolescent: special considerations for management.

Authors:  Lawrence R Stanberry; Susan L Rosenthal
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions.

Authors:  Kenneth H Fife; Tze-Chiang Meng; Daron G Ferris; Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

Review 3.  Genital herpes.

Authors:  Eva Maria Agnes Jungmann
Journal:  BMJ Clin Evid       Date:  2007-04-01

4.  Clinical Evidence: Genital herpes.

Authors:  A Wald
Journal:  West J Med       Date:  1999-06

Review 5.  Current management and recommendations for access to antiviral therapy of herpes labialis.

Authors:  Anthony Cunningham; Paul Griffiths; Peter Leone; Adrian Mindel; Rajul Patel; Lawrence Stanberry; Richard Whitley
Journal:  J Clin Virol       Date:  2011-09-01       Impact factor: 3.168

6.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

7.  Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models.

Authors:  M Lipsitch; T H Bacon; J J Leary; R Antia; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 8.  Genital herpes.

Authors:  Lisa M Hollier; Heather Straub
Journal:  BMJ Clin Evid       Date:  2011-04-15

9.  Beyond efficacy: new issues for HSV antiviral therapy.

Authors:  A Wald
Journal:  Genitourin Med       Date:  1997-04

10.  Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways.

Authors:  Maria Dulfary Sanchez; Augusto C Ochoa; Timothy P Foster
Journal:  Antiviral Res       Date:  2016-05-15       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.